CD20 antibodies

CD20 antibodies

Clone: REA780
REA780 recognizes the human CD20 antigen, a non-glycosylated transmembrane protein of 33–37 kDa that is expressed on B lineage cells from the pre–B cell stage to the B cell lymphoblast stage. The antigen is further expressed on most malignant B cells. CD20 is not found on early B cell progenitors or plasma cells. Oligomers of CD20 form a Ca
2+
channel and might function in the regulation of local responses during B cell activation.
Additional information: Clone REA780 displays negligible binding to Fc receptors.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.
Expression of CD20 may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Alternative Names

B1, Bp35, Ly-44, MS4A1, CVID5, LEU-16, MS4A2, S7

Technical specifications

  • Antigen: CD20
  • Clone: REA780
  • Isotype: recombinant human IgG1
  • Alternative names of antigen: B1, Bp35, Ly-44, MS4A1, CVID5, LEU-16, MS4A2, S7
  • Molecular mass of antigen [kDa]: 33
  • Distribution of antigen: B cells, cancer stem cells, dendritic cells, lymphocytes
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: PE-Vio770
  • Selected references

    1. Lamprecht, B. et al. (2008) Aberrant expression of the Tʜ2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood 112(8): 3339-3347
    2. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
    3. Polyak et al. (2002) CD20 Workshop Panel report. In: Leucocyte typing VII, Oxford University Press.
    4. Countouriotis, T. B. et al. (2002) Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 20(3): 215-229
    5. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
    6. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
    7. Maxwell, S. A. et al. (2009) 14-3-3zeta J. Biol. Chem. 284(33): 22379-22389
    8. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
    9. Wood BL et al. (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin. Cytom. 72: 14-22
    10. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of Immunologically Defined Cell Populations by Flow Cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  • Brochures and posters

  • Certificates of Analysis (CoA)

    Please follow this
    link
    to search for certificates by lot number.
Product options: 1
170-080-011

CD20-PE-Vio770

for 100
tests
EUR 485,00